Preparation, Controlled Drug Release, and Cell Viability Evaluation of Tenofovir Alafenamide-Loaded Chitosan Nanoparticles
Küçük Resim Yok
Tarih
2024
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Wiley-V C H Verlag Gmbh
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Tenofovir alafenamide (TAF) is used as a hepatitis B virus (HBV) nucleotide reverse transcriptase inhibitor for the treatment of chronic HBV infection. However, the use of TAF suffers from its poor solubility and low bioavailability. Therefore, this study prepared and characterized chitosan nanoparticles (CHS NPs) loaded with TAF. Morphological findings demonstrated that CHS NPs are roughly spherical and homogeneous in shape. Besides, TAF-loaded CHS NPs displayed the hydrodynamic diameter, zeta potential, and PDI of approximately 340 nm, 48.9 mV, and 0.65, respectively. The encapsulation efficiency is at about 50%, and TAF is released about 93% at the end of 80 hours at pH 7.4. In addition, human hepatocellular carcinoma cells (HepG2) are used for cell viability studies and it is observed that TAF-loaded CHS NPs has 1.24 times less viable cells as compared to the control. Collectively, TAF-loaded CHS NPs could be used as an efficient formulation for the treatment of chronic HBV infection.
Açıklama
Anahtar Kelimeler
chitosan nanoparticles, drug release, HBV prevention, tenofovir alafenamide
Kaynak
Starch-Starke
WoS Q Değeri
Q3
Scopus Q Değeri
Q2
Cilt
76
Sayı
1-2
